Diabetic Nephropathy
Conditions
Interventions
intervention group:liraglutide
control group:standard treatment
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 years 30 ml / min / 1.73 m2; 5. 7% patients with HbA1c <= 10% within three months; 6. Patients who have not received GLP-1R or dpp-4i or sglt2i treatment in the past 10 weeks; 7. Patients with stable dose of ACEI or ARB for at least 4 weeks; 8. Patients who voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with SBP >= 180mmhg or DBP >= 110mmhg; 2. Glp-1ra or dpp-4i were used 3 months before enrollment, and insulin other than NPH insulin or long-acting insulin analogue were used; 3. Fasting blood glucose > 13.9mmol/l (> 250mg / dl); 4. Patients with IgA nephropathy, membranous nephropathy, lupus nephritis and other pathological types by renal biopsy; 5. Patients with diabetic ketoacidosis in recent one year; 6. Patients with maintenance dialysis or kidney transplantation; 7. Patients with liver function damage, and glutamic oxaloacetic transaminase or alanine aminotransferase more than 3 times of the normal upper limit or total bilirubin more than 2 times of the normal upper limit; 8. Patients with other systemic diseases who are receiving hormone or immunosuppressive therapy; 9. Patients with previous or family history of medullary thyroid carcinoma (MTC) and multiple endocrine tumor syndrome type 2 (men2); 10. Patients with severe cardiovascular disease within 8 weeks: myocardial infarction, ischemic heart disease after coronary artery bypass grafting or PCI, congestive heart failure (cardiac function grade III - IV, NYHA rating); 11. Patients with severe cerebrovascular disease within 8 weeks: stroke and obvious neurological dysfunction after stroke; 12. Patients with active gastrointestinal bleeding within three months; 13. Pregnant or lactating women and women who plan pregnancy or have no contraceptive plan; 14. Patients with malignant tumor, or the expected survival time is less than 6 months; 15. Patients with intolerance or allergy to liraglutide; 16. According to the judgment of the researcher, patients with other diseases or conditions that reduce the possibility of enrollment or complicate the enrollment, such as mental illness, frequent changes in living and working environment, are likely to cause loss of follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| urinary albumin creatinine ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of eGFR from baseline; | — |
Countries
China
Contacts
Public ContactFan Ying
Shanghai Sixth People's Hospital
Outcome results
None listed